Gastric carcinoids: biologic behavior and prognosis after differentiated treatment in relation to type

Kurt Borch, Bo Ahrén, Håkan Ahlman, Sture Falkmer, Göran Granérus, Lars Grimelius, Kurt Borch, Bo Ahrén, Håkan Ahlman, Sture Falkmer, Göran Granérus, Lars Grimelius

Abstract

Objective: To analyze tumor biology and the outcome of differentiated treatment in relation to tumor subtype in patients with gastric carcinoid.

Background: Gastric carcinoids may be subdivided into ECL cell carcinoids (type 1 associated with atrophic gastritis, type 2 associated with gastrinoma, type 3 without predisposing conditions) and miscellaneous types (type 4). The biologic behavior and prognosis vary considerably in relation to type.

Methods: A total of 65 patients from 24 hospitals (51 type 1, 1 type 2, 4 type 3, and 9 type 4) were included. Management recommendations were issued for newly diagnosed cases, that is, endoscopic or surgical treatment of type 1 and 2 carcinoids (including antrectomy to abolish hypergastrinemia) and radical resection for type 3 and 4 carcinoids.

Results: Infiltration beyond the submucosa occurred in 9 of 51 type 1, 4 of 4 type 3, and 7 of 9 type 4 carcinoids. Metastases occurred in 4 of 51 type 1 (3 regional lymph nodes, 1 liver), the single type 2 (regional lymph nodes), 3 of 4 type 3 (all liver), and 7 of 9 type 4 carcinoids (all liver). Of the patients with type 1 carcinoid, 3 had no specific treatment, 40 were treated with endoscopic or surgical excision (in 10 cases combined with antrectomy), 7 underwent total gastrectomy, and 1 underwent proximal gastric resection. Radical tumor removal was not possible in 2 of 4 patients with type 3 and 7 of 9 patients with type 4 carcinoid. Five- and 10-year crude survival rates were 96.1% and 73.9% for type 1 (not different from the general population), but only 33.3% and 22.2% for type 4 carcinoids.

Conclusion: Subtyping of gastric carcinoids is helpful in the prediction of malignant potential and long-term survival and is a guide to management. Long-term survival did not differ from that of the general population regarding type 1 carcinoids but was poor regarding type 4 carcinoids.

Figures

https://www.ncbi.nlm.nih.gov/pmc/articles/instance/1357706/bin/10FF1.jpg
FIGURE 1. Cumulative crude survival after the time of diagnosis among 51 patients with type 1 (circles), 4 patients with type 3 (triangles), and 9 patients with type 4 (squares) gastric carcinoid. The difference between type 1 and type 4 was significant (P < 0.0001, log rank test).

References

    1. Modlin IM, Lye KD, Kidd M. A 50-year analysis of 562 gastric carcinoids: small tumor or larger problem? Am J Gastroenterol. 2004;99:23–32.
    1. Soga J. Gastric carcinoids: a statistical evaluation of 1,094 cases collected from the literature. Surg Today. 1997;27:892–901.
    1. Hakanson R, Owman C. Concomitant histochemical demonstration of histamine and catecholamines in enterochromaffin-like cells of gastric mucosa. Life Sci. 1967;6:759–766.
    1. Solcia E, Rindi G, Silini E, et al. Enterochromaffin-like (ECL) cells and their growths: relationships to gastrin, reduced acid secretion and gastritis. Baillieres Clin Gastroenterol. 1993;7:149–165.
    1. Hakanson R, Chen D, Andersson K, et al. The biology and physiology of the ECL cell. Yale J Biol Med. 1994;67:123–134.
    1. Bordi C, D'Adda T, Azzoni C, et al. Hypergastrinemia and gastric enterochromaffin-like cells. Am J Surg Pathol 1995;19(suppl 1):8–19.
    1. Andersson K, Chen D, Mattsson H, et al. Physiological significance of ECL cell histamine. Yale J Biol Med. 1998;71:183–193.
    1. Prinz C, Zanner R, Gerhard M, et al. The mechanism of histamine secretion from gastric enterochromaffin-like cells. Am J Physiol. 1999;277:C845–C855.
    1. Bakke I, Qvigstad G, Sandvik AK, et al. The CCK-2 receptor is located on the ECL cell, but not on the parietal cell. Scand J Gastroenterol. 2001;36:1128–1133.
    1. Hakanson R, Chen D, Lindstrom E, et al. Physiology of the ECL cells. Yale J Biol Med. 1998;71:163–171.
    1. Bordi C, D'Adda T, Azzoni C, et al. Pathogenesis of ECL cell tumors in humans. Yale J Biol Med. 1998;71:273–284.
    1. Borch K, Renvall H, Liedberg G, et al. Relations between circulating gastrin and endocrine cell proliferation in the atrophic gastric fundic mucosa. Scand J Gastroenterol. 1986;21:357–363.
    1. Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology. 1985;88:638–648.
    1. Sjoblom SM, Sipponen P, Miettinen M, et al. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy. 1988;20:52–56.
    1. Solcia E, Capella C, Fiocca R, et al. Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia: a newly recognized association. Am J Surg Pathol. 1990;14:503–513.
    1. Peghini PL, Annibale B, Azzoni C, et al. Effect of chronic hypergastrinemia on human enterochromaffin-like cells: insights from patients with sporadic gastrinomas. Gastroenterology. 2002;123:68–85.
    1. Cadiot G, Lehy T, Mignon M. Gastric endocrine cell proliferation and fundic argyrophil carcinoid tumors in patients with the Zollinger-Ellison syndrome. Acta Oncol. 1993;32:135–140.
    1. Bordi C, Yu JY, Baggi MT, et al. Gastric carcinoids and their precursor lesions: a histologic and immunohistochemical study of 23 cases. Cancer. 1991;67:663–672.
    1. Rindi G, Luinetti O, Cornaggia M, et al. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology. 1993;104:994–1006.
    1. Ahlman H, Kolby L, Lundell L, et al. Clinical management of gastric carcinoid tumors. Digestion 1994;55(suppl 3):77–85.
    1. Gilligan CJ, Lawton GP, Tang LH, et al. Gastric carcinoid tumors: the biology and therapy of an enigmatic and controversial lesion. Am J Gastroenterol. 1995;90:338–352.
    1. Modlin IM, Kida M, Lye KD. Biology and management of gastric carcinoid tumours: a review. Eur J Surg. 2003;168:669–683.
    1. Borch K. Atrophic gastritis and gastric carcinoid tumours. Ann Med. 1989;21:291–297.
    1. Rappel S, Altendorf-Hofmann A, Stolte M. Prognosis of gastric carcinoid tumours. Digestion. 1995;56:455–462.
    1. Rindi G, Bordi C, Rappel S, et al. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg. 1996;20:168–172.
    1. Solcia E, Rindi G, Paolotti D, et al. Natural history, clinicopathologic classification and prognosis of gastric ECL cell tumors. Yale J Biol Med. 1998;71:285–290.
    1. Hirschowitz BI. Clinical aspects of ECL cell abnormalities. Yale J Biol Med. 1998;71:303–310.
    1. Schindl M, Kaserer K, Niederle B. Treatment of gastric neuroendocrine tumors: the necessity of a type-adapted treatment. Arch Surg. 2001;136:49–54.
    1. Eckhauser FE, Lloyd RV, Thompson NW, et al. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery. 1988;104:1046–1053.
    1. Richards AT, Hinder RA, Harrison AC. Gastric carcinoid tumours associated with hypergastrinaemia and pernicious anaemia: regression of tumors by antrectomy: a case report. S Afr Med J. 1987;72:51–53.
    1. Wangberg B, Grimelius L, Granerus G, et al. The role of gastric resection in the management of multicentric argyrophil gastric carcinoids. Surgery. 1990;108:851–857.
    1. D'Adda T, Annibale B, Delle Fave G, et al. Oxyntic endocrine cells of hypergastrinaemic patients: differential response to antrectomy or octreotide. Gut. 1996;38:668–674.
    1. Higham AD, Dimaline R, Varro A, et al. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology. 1998;114:817–822.
    1. Delle Fave G, Annibale B. Modulation of growth of human gastric enterochromaffin-like cells. Digestion 1996;57(suppl 1):15–16.
    1. Modlin IM, Lawton GP, Miu K, et al. Pathophysiology of the fundic enterochromaffin-like (ECL) cell and gastric carcinoid tumours. Ann R Coll Surg Engl. 1996;78:133–138.
    1. Ichikawa J, Tanabe S, Koizumi W, et al. Endoscopic mucosal resection in the management of gastric carcinoid tumors. Endoscopy. 2003;35:203–206.
    1. Ahren B, Borch K. Multiple gastric carcinoid tumours. Eur J Surg. 1995;161:375.
    1. Bordi C, Cocconi G, Togni R, et al. Gastric endocrine cell proliferation: association with Zollinger-Ellison syndrome. Arch Pathol. 1974;98:274–278.
    1. Granerus G, Lonnqvist B, Wass U. Determination of the histamine metabolite tele-methylimidazoleacetic acid and of creatinine in urine by the same HPLC system. Inflamm Res. 1999;48:75–80.
    1. Rubin W, Schwartz B. Electron microscopic radioautographic identification of the ECL cell as the histamine-synthesizing endocrine cell in the rat stomach. Gastroenterology. 1979;77:458–467.
    1. Solcia E, Capella C, Buffa R, et al. The diffuse endocrine-paracrine system of the gut in health and disease: ultrastructural features. Scand J Gastroenterol Suppl. 1981;70:25–36.
    1. Borch K, Renvall H, Kullman E, et al. Gastric carcinoid associated with the syndrome of hypergastrinemic atrophic gastritis: a prospective analysis of 11 cases. Am J Surg Pathol. 1987;11:435–444.
    1. Modlin IM, Sandor A, Tang LH, et al. A 40-year analysis of 265 gastric carcinoids. Am J Gastroenterol. 1997;92:633–638.
    1. Borch K, Kullman E, Hallhagen S, et al. Increased incidence of pancreatic neoplasia in pernicious anemia. World J Surg. 1988;12:866–870.
    1. Gough DB, Thompson GB, Crotty TB, et al. Diverse clinical and pathologic features of gastric carcinoid and the relevance of hypergastrinemia. World J Surg 1994;18:473–479; discussion 479–480.
    1. Kolby L, Wangberg B, Ahlman H, et al. Gastric carcinoid with histamine production, histamine transporter and expression of somatostatin receptors. Digestion. 1998;59:160–166.
    1. Modlin IM, Lye KD, Kidd M. Carcinoid tumors of the stomach. Surg Oncol. 2003;12:153–172.
    1. Thomas RM, Baybick JH, Elsayed AM, et al. Gastric carcinoids: an immunohistochemical and clinicopathologic study of 104 patients. Cancer. 1994;73:2053–2058.
    1. Harvey RF. Spontaneous resolution of multifocal gastric enterochromaffin-like cell carcinoid tumours. Lancet. 1988;8589:821.
    1. Brundler R, Gebbers JO, Criblez D. Multiple gastric carcinoid tumors in chronic atrophic gastritis: long-term follow-up under conservative management. Schweiz Med Wochenschr. 1999;129:957–960.
    1. Granberg D, Wilander E, Stridsberg M, et al. Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids. Gut. 1998;43:223–228.
    1. Guillem P, Vlaeminck-Guillem V, Leteurtre E, et al. Fundic endocrine tumors and atrophic gastritis: the value of antrectomy. Gastroenterol Clin Biol. 2002;26:782–785.
    1. Hagarty S, Huttner I, Shibata H, et al. Gastric carcinoid tumours and pernicious anemia: case report and review of the literature. Can J Gastroenterol. 2000;14:241–245.
    1. Hirschowitz BI, Griffith J, Pellegrin D, et al. Rapid regression of enterochromaffinlike cell gastric carcinoids in pernicious anemia after antrectomy. Gastroenterology. 1992;102:1409–1418.
    1. Kern SE, Yardley JH, Lazenby AJ, et al. Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morphometric study. Mod Pathol. 1990;3:561–566.
    1. Stolte M, Ebert D, Seifert E, et al. The prognosis of carcinoid tumors of the stomach. Leber Magen Darm. 1988;18:246–250, 253–256.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe